Overview
Clinical Meaning
The clinician managing personality disorders navigates the complex pharmacotherapy landscape where no medications are FDA approved for any PD, yet symptom targeted prescribing i...
The clinician managing personality disorders navigates the complex pharmacotherapy landscape where no medications are FDA-approved for any PD, yet symptom-targeted prescribing is common and sometimes necessary. Evidence-based guidelines (NICE, APA, Cochrane reviews) generally advise AGAINST polypharmacy for BPD and recommend pharmacotherapy only for specific symptom domains or comorbid conditions. The NP's primary role is coordinating evidence-based psychotherapy (DBT for BPD) while judiciously prescribing for specific targets. Symptom domain approach: (1) Affective dysregulation (mood instability, intense anger, emotional lability) -- mood stabilizers (lamotrigine has most evidence in BPD; valproic acid; lithium less studied), SSRIs; (2) Impulsive-behavioral dyscontrol (self-harm, substance use, binge eating, reckless behavior) -- mood stabilizers, SSRIs, naltrexone (for endorphin-mediated self-harm); (3) Cognitive-perceptual disturbances (transient paranoia, dissociation, ideas of reference) -- low-dose atypical antipsychotics; (4) Comorbid conditions (MDD, GAD, PTSD, ADHD, eating disorders, SUD) -- standard evidence-based treatment for each. The clinician must resist pressure to add medications for each presenting symptom, recognizing that polypharmacy without evidence base is a significant problem in PD treatment. Regular medication review with tapering of ineffective agents is essential.